ReviewAntioxidants (Basel, Switzerland)2025
Microbial-Derived Antioxidants in Intestinal Inflammation: A Systematic Review of Their Therapeutic Potential.
Review in Antioxidants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Postbiotics Formulation and Therapeutic Effect in Inflammation: A Systematic Review.Nutrients · 2025Pooled it
- Beyond Probiotics: Postbiotics for Healthy Aquaculture.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Fisetin alleviates zinc overload-induced intestinal injury by inhibiting ferroptosis and remodeling gut microbiota in weaned piglets.Journal of animal science and biotechnology · 2026Article
- Cheonggukjang-DerivedMetabolites · 2026Article
- Oxidative Stress-Gut Microbiome Crosstalk: Intestinal Redox Imbalance and Probiotics Therapeutic Potential.Antioxidants (Basel, Switzerland) · 2026Review
- Targeted intestinal barrier repairActa pharmaceutica Sinica. B · 2026Article
- Probiotic and immune-modulatory capacities of three human gut-derived strains of Parabacteroides distasonis.Archives of microbiology · 2026Article
- Interplay of Microbiome, Oxidative Stress and Inflammation in Health and Disease.Antioxidants (Basel, Switzerland) · 2026Review
- Glucan exopolysaccharide fromFrontiers in molecular biosciences · 2026Article
- Multi-omics integration of gut-skin axis in probiotic-treated dermatological conditions.Frontiers in cellular and infection microbiology · 2026Article
- Insights into biosynthesis, regulation, and functional potentials of exopolysaccharide from Leptolyngbya sp. MKU-05.World journal of microbiology & biotechnology · 2025Article
- The Gfr Uptake System Provides a Context-Dependent Fitness Advantage to Salmonella Typhimurium SL1344 During the Initial Gut Colonization Phase.Molecular microbiology · 2025Article
- The Protective Effects ofFood science & nutrition · 2025Article
- Dietary ProbioticAntioxidants (Basel, Switzerland) · 2025Article
- Role of Antioxidants in Modulating the Microbiota-Gut-Brain Axis and Their Impact on Neurodegenerative Diseases.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The potential of microbial-derived antioxidants to modulate intestinal inflammation is increasingly recognized, which is especially important in inflammatory bowel diseases (IBD). Oxidative stress, a major contributor to chronic intestinal inflammation, is the result of an imbalance between the production of reactive oxygen species (ROS) and the body's antioxidant defenses. This systematic review explores the role of microbial-derived antioxidants in alleviating IBD. Among the main findings are certain compounds, such as exopolysaccharides (EPS) and short-chain fatty acids (SCFAs), which have demonstrated their ability to neutralize ROS and strengthen the integrity of the intestinal barrier, thereby attenuating inflammatory responses. These antioxidants offer the dual benefit of mitigating oxidative stress and rebalancing the gut microbiota, which is often disrupted in IBD. Evidence from preclinical and clinical studies provides a better understanding of the mechanisms involved in the effects of these microbial antioxidants. Conventional treatments for IBD primarily focus on immune modulation. In this context, the integration of microbial-derived antioxidants could offer a complementary approach by addressing both oxidative damage and gut dysbiosis. Further research and clinical trials are essential to establish standardized treatment guidelines and clarify the long-term efficacy of these promising therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.